相似文献
1
Design of studies on neoadjuvant therapy for intrahepatic cholangiocarcinoma.
Heliyon. 2024 Dec 25;11(2):e41356. doi: 10.1016/j.heliyon.2024.e41356. eCollection 2025 Jan 30.
2
Advances in immunotherapy for biliary tract cancers.
Chin Med J (Engl). 2024 Mar 5;137(5):524-532. doi: 10.1097/CM9.0000000000002759. Epub 2023 Aug 29.
3
Management of Intrahepatic Cholangiocarcinoma: A Narrative Review.
Cancers (Basel). 2024 Feb 10;16(4):739. doi: 10.3390/cancers16040739.
4
Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.
BMC Cancer. 2022 Nov 16;22(1):1178. doi: 10.1186/s12885-022-10286-z.
5
Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.
J Clin Transl Hepatol. 2022 Jun 28;10(3):553-563. doi: 10.14218/JCTH.2021.00250. Epub 2022 Jan 4.
6
Neoadjuvant and adjuvant therapy for biliary tract cancer: Advances and limitations.
Hepatology. 2024 Jan 24. doi: 10.1097/HEP.0000000000000760.
7
Broadening the therapeutic horizon of advanced biliary tract cancer through molecular characterisation.
Cancer Treat Rev. 2020 Jun;86:101998. doi: 10.1016/j.ctrv.2020.101998. Epub 2020 Mar 12.
8
The state of therapy modalities in clinic for biliary tract cancer.
Front Biosci (Landmark Ed). 2022 Jun 8;27(6):185. doi: 10.31083/j.fbl2706185.
9
Complete Pathological Response to Neoadjuvant Chemoimmunotherapy in a Patient With Metastatic Intrahepatic Cholangiocarcinoma With High Tumor Mutational Burden.
Cureus. 2021 Dec 5;13(12):e20187. doi: 10.7759/cureus.20187. eCollection 2021 Dec.
10
Surgical Treatment of Intrahepatic Cholangiocarcinoma: Current and Emerging Principles.
J Clin Med. 2020 Dec 30;10(1):104. doi: 10.3390/jcm10010104.
本文引用的文献
1
SWOG S1815: A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers.
J Clin Oncol. 2025 Feb 10;43(5):536-544. doi: 10.1200/JCO-24-01383. Epub 2024 Dec 13.
2
Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
NEJM Evid. 2022 Aug;1(8):EVIDoa2200015. doi: 10.1056/EVIDoa2200015. Epub 2022 Jun 1.
3
RLY-4008, the First Highly Selective FGFR2 Inhibitor with Activity across FGFR2 Alterations and Resistance Mutations.
Cancer Discov. 2023 Sep 6;13(9):2012-2031. doi: 10.1158/2159-8290.CD-23-0475.
4
Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet. 2023 Jun 3;401(10391):1853-1865. doi: 10.1016/S0140-6736(23)00727-4. Epub 2023 Apr 16.
5
Are more courses of immunochemotherapy beneficial for the short-term outcome of locally advanced esophageal squamous cell carcinoma?
Thorac Cancer. 2023 May;14(13):1153-1161. doi: 10.1111/1759-7714.14843. Epub 2023 Mar 24.
6
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study.
Signal Transduct Target Ther. 2023 Mar 17;8(1):106. doi: 10.1038/s41392-023-01317-7.
7
Adjuvant S-1 compared with observation in resected biliary tract cancer (JCOG1202, ASCOT): a multicentre, open-label, randomised, controlled, phase 3 trial.
Lancet. 2023 Jan 21;401(10372):195-203. doi: 10.1016/S0140-6736(22)02038-4.
8
Futibatinib for -Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med. 2023 Jan 19;388(3):228-239. doi: 10.1056/NEJMoa2206834.
9
Cancer statistics, 2023.
CA Cancer J Clin. 2023 Jan;73(1):17-48. doi: 10.3322/caac.21763.
10
Epidemiologic patterns of biliary tract cancer in the United States: 2001-2015.
BMC Cancer. 2022 Nov 16;22(1):1178. doi: 10.1186/s12885-022-10286-z.
Zotero 插件